Opus Genetics, Inc.
NASDAQ: IRD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- George Magrath
- Employees
- 18
- Headquarters
- Durham, United States
- IPO year
- 2015
- Market cap
- $306.3M
- Website
- https://opusgtx.com
Loading IRD…
Loading profile data…Frequently asked questions about IRD
What does Opus Genetics, Inc. (IRD) do?
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently...
Where does IRD trade?
Opus Genetics, Inc. (IRD) trades on the NASDAQ Global Market.
What sector is IRD in?
Opus Genetics, Inc. (IRD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Opus Genetics, Inc.?
George Magrath is the chief executive officer of Opus Genetics, Inc. (IRD).
Where is Opus Genetics, Inc. headquartered?
Opus Genetics, Inc. is headquartered in United States.
Does IRD pay a dividend?
Opus Genetics, Inc. (IRD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IRD go public?
Opus Genetics, Inc. (IRD) completed its initial public offering in 2015.